Alloy and Evernow both publish menopause treatment options, but their headline prices describe different things. Alloy's catalog emphasizes medications; Evernow describes both video visits and membership-based care, with medication priced separately.
We compared their official pages on September 21, 2026. This is a practical comparison of published offerings, not evidence that one provider's prescriptions work better. The right medication, if any, depends on a clinician's assessment of your symptoms and health history.
Start with the same treatment need
Hot flashes and vaginal dryness do not always call for the same prescription. Both providers list multiple hormone products, but a low-dose vaginal treatment should not be priced as if it replaces systemic therapy for hot flashes. Decide with a clinician what treatment is being considered before comparing the bills.
The vaginal-versus-systemic explanation helps identify that distinction. If your symptoms or medical history call for an examination, neither a delivery service nor secure messaging removes that need.
Alloy's catalog gives product-level figures
Alloy lists an estradiol pill starting at $39.99 per month, a patch at $100 and gel or spray at $69.99. It also lists progesterone starting at $23. These are separate catalog entries, not interchangeable prescriptions and not proof that every care plan has the same total.
Ask what must be purchased together, how many months are charged at once and whether the consultation adds a fee. If you have a uterus, the clinician should discuss appropriate protection of the uterine lining when systemic estrogen is prescribed. A patch-only price can therefore be an incomplete comparison.
Evernow separates care and medication
Evernow lists a $150 uninsured video appointment and membership plans starting at $35 per month. Medication costs are separate, with local pharmacy pickup or home delivery described. Do not compare $35 of membership access with $100 of medication as if both numbers buy the same service.
Ask whether you need a membership, a video visit or both for your chosen route. Then get the prescription cost through the intended pharmacy. Our local-pharmacy shortlist provides other options if keeping an existing pharmacy is a priority.
Insurance is another separate calculation
Evernow says it accepts certain commercial insurance plans for video visits and describes possible medication coverage through a local pharmacy. The exact plan, deductible and prescription still need verification. Those statements should not be stretched into a promise that a monthly membership is reimbursed.
For Alloy, obtain the terms attached to the actual product and order. Do not assume a catalog price is an insurance copay. Compare the amount due now and the recurring cost over the same period, including any additional prescribed medicine or follow-up appointment.
Check the actual formulation
Evernow's FAQ includes compounded bioidentical formulations among its options. Alloy sells several categories of products, including compounded items outside its standard menopause hormone menu. Neither company's entire catalog should be labeled FDA-approved merely because some products have approval. The compounding guide explains the distinction.
Ask for the medication's name, route and approval status. A review of provider websites cannot establish comparative effectiveness of compounded preparations, and testimonials cannot fill that evidence gap.
Which questions decide the fit
Alloy may warrant a closer look when its product and delivery arrangement matches an agreed treatment plan. Evernow may warrant a closer look when choosing between ongoing messaging, a video appointment and a preferred pharmacy is central to the decision. Confirm those terms before paying.
If a patch is the specific topic, use the estradiol patch shortlist. It compares practical access questions without recommending a dose, guaranteeing inventory or calling one provider medically superior.
FOLLOW THE EVIDENCE
Sources & further reading
Provider pages support service and price descriptions. Medical guidance supports treatment explanations. Neither is a first-hand review of patient outcomes. Latest source check: September 21, 2026.